Figure 1

![Figure 1: Study flow chart for the ACE-2020-EGb761 randomized open-label clinical trial in mild cognitive impairment. The Phase IV single-center design examines blood markers of inflammation and oxidative stress with Ginkgo biloba extract (EGb 761) treatment.]()

> Source: Xavier Morató et al. "A randomized, open-label clinical trial in mild cognitive impairment with EGb 76." *Scientific reports*, 2023. PMID: [37012306](https://pubmed.ncbi.nlm.nih.gov/37012306/)

<figure>
  <img src="" alt="Study flow chart for the ACE-2020-EGb761 randomized open-label clinical trial in mild cognitive impairment. The Phase IV single-center design examines blood markers of inflammation and oxidative stress with Ginkgo biloba extract (EGb 761) treatment." />
  <figcaption>Figure 1. Study flow chart for the ACE-2020-EGb761 randomized open-label clinical trial in mild cognitive impairment. The Phase IV single-center design examines blood markers of inflammation and oxidative stress with Ginkgo biloba extract (EGb 761) treatment.<br>  Source: Xavier Morató et al. "A randomized, open-label clinical trial in mild cognitive impairment with EGb 76." <em>Scientific reports</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37012306/">37012306</a></figcaption>
</figure>